PetDx

PetDx – The Liquid Biopsy Company for Pets is a San Diego-based molecular diagnostics company that has developed OncoK9 – The Liquid Biopsy Test for Dogs. This pioneering test enables veterinarians to detect cancer in dogs with a simple blood draw. OncoK9 is a first-in-class multi-cancer early detection (MCED) test that employs cutting-edge genomic analysis, leveraging next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms.

The test can detect 30 different types of canine cancer, with sensitivity of 85.4% for three of the most aggressive cancers (lymphoma, hemangiosarcoma, and osteosarcoma) and overall sensitivity of 54.7%, at a specificity of 98.5% (corresponding to a false positive rate of just 1.5%). These performance metrics mirror those of leading MCED tests for humans.

OncoK9 is currently recommended as an annual screening test for dogs at higher risk of cancer due to age and/or breed, and as an aid-in-diagnosis for dogs in which cancer is suspected based on clinical signs or other clinical findings. Since its launch in 2021, the test has been successfully integrated into routine testing at thousands of leading veterinary practices across the US and Canada as a new preventive care and aid-in-diagnosis tool. PetDx's centralized laboratory in San Diego processes samples shipped from across North America daily, with results delivered to ordering veterinarians within 10 business days.